Bovie Medical Corporation Announces Third Quarter Financial Results; Files Patent For New J-Plasma™ Handpiece
Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the third quarter and nine months ended September 30, 2010.
Revenues for the third quarter ended September 30, 2010 increased 2% to $6,501,163 versus $6,371,371 for the comparable period last year; resulting in net income of $4,236 or $0.00 per diluted share as compared to net loss of $(37,749) or $.00 per diluted share in the same period last year.
Revenues in the third quarter were positively impacted by an increase in sales of generators, electrodes and cauteries both domestically and internationally offsetting a reduction in the sale of OEM ablator deliveries.
Revenues for the nine months ended September 30, 2010 were $17,997,180 versus $20,420,272 for the comparable period last year; resulting in net loss of $(165,774) or $(0.01) per diluted share as compared to net income of $568,136 or $.03 per diluted share in the same period in the prior year.Subsequent to the close of the third quarter, the Company received net cash proceeds of $633,000 for the sale of its old facility located at 7100 30 th Avenue North, St. Petersburg, Florida. Andrew Makrides, president of Bovie, stated, “With continued improvement in current electrosurgical sales, management is encouraged that, as 2011 approaches, future growth can be realized with the introduction of new product lines marketed by our increased number of independent sales reps, now totaling 37.” NEW PRODUCT ACTIVITIES J-Plasma™ The Company recently submitted a 510(k) application with the Food and Drug Administration (FDA) to market a new handpiece with retractable cutting features to be used in both laparoscopic and open procedures. On November 8, 2010 Bovie filed additional patents for its new J-Plasma™ handpiece. Surgeons in diverse specialties are being engaged for testing and feedback for potential use in open and laparoscopic surgical applications for the J-Plasma™ system. We are also exploring possibilities that the J-Plasma™ technology could be useful in promoting wound healing, viral/bacterial mitigation and oncology applications.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV